All News
Filter News
Found 153 articles
-
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
11/2/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the third quarter 2023.
-
Nonalcoholic Steatohepatitis (NASH) Market to Observe Stunning Growth by 2032 Owing to a Robust Pipeline
11/1/2023
The NASH market is expected to evolve because of emerging therapies like MGL-3196, Semaglutide, Vonafexor, HPG1860, VK2809, BIO89-100, LPCN 1144, and others.
-
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
10/26/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that announced that it will report the Company’s third quarter 2023 financial results on Thursday, November 2, 2023, after the close of the U.S. financial markets.
-
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
10/25/2023
Aligos Therapeutics, Inc. today announced that an abstract for its capsid assembly modulator – empty (CAM-E) drug candidate, ALG-000184, has been accepted as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD).
-
Aligos Therapeutics Announces $92 Million Private Placement Financing
10/23/2023
Aligos Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $92 million, before deducting placement agent fees and other expenses, to advance its portfolio of drug candidates.
-
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
10/3/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has been awarded an $8.5 million National Institute of Allergy and Infectious Diseases (NIAID) contract to conduct nonclinical and clinical studies to advance its pan-coronavirus protease inhibitor ALG-097558 into future Phase 2/3 studies.
-
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024
9/21/2023
Aligos Therapeutics, Inc. announced it has received clearance of its Investigational New Drug application from the US Food and Drug Administration for ALG-055009, it’s thyroid hormone receptor beta agonist, intended for the treatment of nonalcoholic steatohepatitis.
-
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
8/3/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2023.
-
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
7/27/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company’s second quarter 2023 financial results on Thursday, August 03, 2023, after the close of the U.S. financial markets.
-
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
7/19/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the selection of Stephen Harrison, MD as principal investigator of, and key design elements for, its upcoming Ph2a study of NASH drug candidate ALG-055009.
-
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
6/21/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company is presenting several posters collectively highlighting data from its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.
-
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
6/7/2023
Aligos Therapeutics, Inc. today announced that the company will present seven posters collectively highlighting data on its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.
-
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
5/24/2023
Aligos Therapeutics, Inc. announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. ET.
-
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
5/12/2023
Aligos Therapeutics, Inc. announced that it has entered into a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. for the use of Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.
-
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
5/4/2023
Aligos Therapeutics, Inc. reported recent business progress and financial results for the first quarter 2023.
-
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
4/27/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”) today announced that it will report the Company’s first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets.
-
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
4/11/2023
Aligos Therapeutics, Inc. announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the European Association for the Study of the Liver Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.
-
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
3/29/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company presented Phase 1 data for its thyroid receptor-beta (THR-ß) agonist candidate, ALG-055009, at the 15th Paris Hepatology Conference, taking place virtually March 27 – 29, 2023.
-
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
3/9/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2022.
-
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
2/28/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”) today announced that it will report the Company’s fourth quarter 2022 financial results on Thursday, March 9, 2023 after the close of the U.S. financial markets.